Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma is a type of blood cancer that occurs when multiple myeloma returns after treatment or does not respond to therapy, leading to symptoms such as bone pain, fatigue, and anemia.
Multiple Myeloma: JNJ-87562761 Treatment
We are testing a new drug for patients with relapsed or refractory multiple myeloma. The goal is to understand its safety and how it affects the disease.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut Catala D'oncologia
Hemarología
Badalona, Spain
Clinica Universidad De Navarra
Ensayos Clínicos de Hematología
Barañáin, Spain
Hospital Clinic De Barcelona
Hematología
El Altet, Spain
Sponsor: Janssen Cilag International
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.